Press Release
Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SEONGNAM, South Korea and BOSTON, Dec. 30, 2024 /PRNewswire/ — Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that James Jungkue Lee, Founder and CEO of Bridge Biotherapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025.
Location: Georgian Room (Mezzanine Level) at The Westin St. Francis
Date: Thursday, January 16, 2025
Time: 9:45-10:25 a.m. PST
During the conference, Bridge Biotherapeutics will also meet with potential partners and investors as the Company is looking for Business Development opportunities for further development of BBT-877, a novel drug candidate for idiopathic pulmonary fibrosis (IPF). Top-line results from the Phase 2 study of BBT-877 are expected in April 2025.
To arrange a meeting with the Bridge Biotherapeutics team, send a meeting request here.
About Bridge Biotherapeutics, Inc.
Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S., is a publicly traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including fibrotic diseases and cancers. The company is developing BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-207, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S mutations. Learn more at https://www.bridgebiorx.com/en/.
Source : Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
The information provided in this article was created by Cision PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of ThailandChina.
Corporate
Will you still have an office in the post Covid-19 world?
Businesses waste vast resources paying leases for real estate they simply don’t need. Flexible working spaces are a vital way of ensuring that no longer happens.
HONG KONG – (ACN Newswire) – While the pandemic has led many to believe remote work will become the norm, concerns about lagging creativity and loneliness show that there is still a role for the office in a post Covid-19 world, according to The Executive Centre (TEC).
(more…)Markets
Tiger Trade Launches SGX Trading, Meeting Demand from Asian Investors
Access to the Singapore Exchange (SGX) adds to Tiger Brokers’ current menu of stock exchanges, such as the New York Stock Exchange (NYSE) and the Nasdaq Stock Market (NASDAQ), the world’s two largest stock exchanges, as well as the Hong Kong Stock Exchange (HKEX).
SINGAPORE (ACN Newswire) – Tiger Trade, a one-stop mobile and online trading application by Tiger Brokers, has launched access to the Singapore Exchange (SGX).
(more…)Health
APRIL International Care opens up TeleHEALTH service to address Coronavirus worries
The TeleHEALTH service means policyholders do not have to leave their home or workplace to “see” a doctor, with a consultation happening directly over the phone
Hong Kong February 10, 2020 – APRIL International Care has opened up its TeleHEALTH service to all individual and group clients across its Asian region to provide support for clients during the current Coronavirus outbreak.
(more…)- China-linked Hackers Compromised US Treasury Workstations | CNN Business
- Introducing Our 2025 Guide to Corporate Taxation and Compliance in China – Now Available!
- Brics+ countries are determined to trade in their own currencies – but can it work?
- Previously Unseen Photos of Joe and Hunter Biden in China Spark New Questions About Son’s Business Ventures for the President
- China and India Foster Trust on the Road to Reconciliation
- Nigeria and China Revive Currency Swap Agreement – Guardian Nigeria
